Severity Indices News Today

Nearly two thirds of ED visits by patients with acute pulmonary embolism resulted in unnecessary hospitalization, suggested a new study.

In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.

Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.

Underrepresentation of Black patients with psoriasis in trials and textbooks might partially explain why clinicians are slow to recognize nail involvement, even after psoriasis has been diagnosed.

Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.

New research spotlights the impact that individual healthcare worker’s actions can have on burnout, an aspect that is often overlooked in current discussions regarding professional well-being.

The study is investigating whether high-dose IL-23 inhibition can target resident memory T cells and thereby induce long-term remission.

"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.

To date, the study is the largest to explore the relationship between severe psoriasis and coronary microvascular dysfunction.

"Limited topical treatments are approved for children younger than 12 years old with psoriasis."